Compare LOAN & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LOAN | IXHL |
|---|---|---|
| Founded | 1989 | 2001 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.9M | 97.6M |
| IPO Year | 1999 | 2024 |
| Metric | LOAN | IXHL |
|---|---|---|
| Price | $4.40 | $5.95 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 20.3K | ★ 4.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 9.96% | N/A |
| EPS Growth | ★ 2.08 | N/A |
| EPS | ★ 0.35 | N/A |
| Revenue | ★ $9,688,641.00 | $12,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.47 | N/A |
| P/E Ratio | $12.69 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.24 | $0.11 |
| 52 Week High | $6.05 | $5.45 |
| Indicator | LOAN | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 49.56 | 90.18 |
| Support Level | $4.29 | $0.31 |
| Resistance Level | $4.59 | N/A |
| Average True Range (ATR) | 0.08 | 0.37 |
| MACD | 0.01 | 0.40 |
| Stochastic Oscillator | 76.45 | 91.05 |
Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.